| Company Name: |
Eastbang Pharmaceuticals Technology Co., Ltd. |
| Tel: |
+86 (20) 28996708,29078958,28139708,29076128,28133708,28139728,28139738,28133718,021-31663278,021-31663578,021-60538387 |
| Email: |
|
Ziprasidone mesilate manufacturers
- Ziprasidone mesilate
-
- $1.00
-
2020-01-10
- CAS:199191-69-0
- Min. Order: 1g
- Purity: 98%
- Supply Ability: 200kgs
|
| | Ziprasidone mesilate Basic information |
| Product Name: | Ziprasidone mesilate | | Synonyms: | 2H-INDOL-2-ONE, 5-[2-[4-(1,2-BENZISOTHIAZOL-3-YL)-1-PIPERAZINYL]ETHYL]-6-CHLORO-1,3-DIHYDRO-, MONOMETHANESULFONATE, TRIHYDRATE;5-[2-[4-(1,2-benzisothiazol-3yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-2h-indol-2-one mesilate;ziprasidone mesilate;ZIPRASIDONE MESYLATE;Ziprasidone mesylate trihydrate;2H-Indol-2-one, 5-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-1,3-dihydro-,monomethanesulfonate, trihydrate;Ziprasidone mesilate trihydrate CRS;Ziprasidone (mesylate hydrate) | | CAS: | 199191-69-0 | | MF: | C22H31ClN4O7S2 | | MW: | 563.09 | | EINECS: | | | Product Categories: | | | Mol File: | 199191-69-0.mol |  |
| | Ziprasidone mesilate Chemical Properties |
| Major Application | pharmaceutical (small molecule) | | InChIKey | WLQZEFFFIUHSJB-UHFFFAOYSA-N | | SMILES | C1(N2CCN(CC2)CCC2=CC3CC(=O)NC=3C=C2Cl)C2C=CC=CC=2SN=1.S(C)(O)(=O)=O.O.O.O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids | | Hazard Classifications | Skin Sens. 1 STOT RE 2 |
| | Ziprasidone mesilate Usage And Synthesis |
| Uses | Antipsychotic (central D2and 5HT2receptor antagonist). | | Definition | ChEBI: The methanesulfonate trihydrate salt of ziprasidone. | | Brand name | Geodon (Pfizer). | | in vivo | Ziprasidone mesylate trihydrate (oral gavage; 20 mg/kg; once daily; 7 weeks) results in weight loss, low level physical activity, high resting energy expenditure and greater capacity for thermogenesis when subjected to cold[3]. | Animal Model: | Eight-week-old female Sprague-Dawley rats weighing 200 to 250 g[3] | | Dosage: | 20 mg/kg | | Administration: | Oral gavage; 20 mg/kg; once daily; 7 weeks | | Result: | Gained significantly less weight (P = 0.031), had a lower level of physical activity (P = 0.016), showed a higher resting energy expenditure (P < 0.001), and displayed a greater capacity for thermogenesis when subjected to cold (P < 0.001). |
| | IC 50 | Rat 5-HT2 Receptor: 0.42 nM (Ki); Rat 5-HT1A Receptor: 3.4 nM (Ki); Rat D2 Receptor: 4.8 nM (Ki) |
| | Ziprasidone mesilate Preparation Products And Raw materials |
|